deltatrials
Terminated PHASE2 INTERVENTIONAL NCT00141310

Sildenafil Citrate for the Treatment of Established Pre-Eclampsia

A Randomised, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel-Group Study to Evaluate the Efficacy, Safety and Toleration of Oral Sildenafil Citrate Administered in the Dose Range of 20 - 80 Mg TID for the Treatment of Pre-Eclampsia. (PET)

Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Conditions Pre-eclampsia
Interventions Sildenafil citrate
Updated 12 times since 2017 Last updated: Jan 28, 2021 Started: Sep 30, 2004 Completion: Apr 30, 2006
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study prematurely discont'd 20-Apr-2006 after interim analysis suggested sample size could be reduced without losing power. No safety concerns led to decision.

Other terminated trials from Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

More terminations from Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

A PHASE2 clinical study on Pre-eclampsia, this trial is terminated or withdrawn. The trial is conducted by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. and has accumulated 12 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Aug 2017 · 7 months · monthly snapshotTerminated~Aug 2017 – ~May 2018 · 9 months · monthly snapshotTerminated~May 2018 – ~Jun 2018 · 31 days · monthly snapshotTerminated~Jun 2018 – ~Sep 2020 · 27 months · monthly snapshotTerminated~Sep 2020 – ~Nov 2020 · 2 months · monthly snapshotTerminated~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshotTerminated~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshotTerminated~Mar 2021 – ~Dec 2021 · 9 months · monthly snapshotTerminated~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotTerminated~Sep 2025 – present · 10 months · monthly snapshotTerminated

Change History

12 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  4. Dec 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  5. Mar 2021 — Dec 2021 [monthly]

    Terminated PHASE2

▶ Show 7 earlier versions

  1. Jan 2021 — Mar 2021 [monthly]

    Terminated PHASE2

  2. Nov 2020 — Jan 2021 [monthly]

    Terminated PHASE2

  3. Sep 2020 — Nov 2020 [monthly]

    Terminated PHASE2

  4. Jun 2018 — Sep 2020 [monthly]

    Terminated PHASE2

  5. May 2018 — Jun 2018 [monthly]

    Terminated PHASE2

  6. Aug 2017 — May 2018 [monthly]

    Terminated PHASE2

  7. Jan 2017 — Aug 2017 [monthly]

    Terminated PHASE2

    First recorded

Sep 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations